Diarrhea - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 164
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: DAA06A1D26DEN
Leaflet:

Download PDF Leaflet

Diarrhea - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Diarrhea - Pipeline Review, H2 2016’, provides an overview of the Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Diarrhea
  • The report reviews pipeline therapeutics for Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diarrhea therapeutics and enlists all their major and minor projects
  • The report assesses Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diarrhea
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diarrhea
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Diarrhea Overview
Therapeutics Development
Pipeline Products for Diarrhea - Overview
Pipeline Products for Diarrhea - Comparative Analysis
Diarrhea - Therapeutics under Development by Companies
Diarrhea - Therapeutics under Investigation by Universities/Institutes
Diarrhea - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diarrhea - Products under Development by Companies
Diarrhea - Products under Investigation by Universities/Institutes
Diarrhea - Companies Involved in Therapeutics Development
A. Menarini Industrie Farmaceutiche Riunite Srl
Ache Laboratorios Farmaceuticos S/A
Actelion Ltd
Aegis Therapeutics, LLC
AlbireoPharma
Allergan Plc
Anatara Lifesciences Limited
Ardelyx, Inc.
Assembly Biosciences, Inc.
Codagenix, Inc.
Cosmo Pharmaceuticals S.p.A
DesignMedix, Inc.
DiscoveryBiomed, Inc.
Genextra S.p.a.
GlaxoSmithKline Plc
GP Pharm, S.A.
Mucosis B.V.
Nippon Shinyaku Co., Ltd.
Novartis AG
Pfizer Inc.
Prokarium Limited
Protagonist Therapeutics Inc.
Rebiotix Inc.
Recce Pty Ltd
RxBio, Inc.
Scandinavian Biopharma Holding AB
Sigmoid Pharma Limited
Summit Therapeutics Plc
Synthetic Biologics, Inc.
Syntiron LLC
Tasly Pharmaceutical Group Co., Ltd.
Diarrhea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ABM-101 - Drug Profile
ACH-04 - Drug Profile
ASP-7147 - Drug Profile
cadazolid - Drug Profile
Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile
cholestyramine - Drug Profile
Clostridium difficile vaccine - Drug Profile
crofelemer DR - Drug Profile
Drug for Diarrhea - Drug Profile
eluxadoline - Drug Profile
Escherichia coli vaccine - Drug Profile
ETEC vaccine - Drug Profile
ETEC vaccine - Drug Profile
Etvax - Drug Profile
GVXNSD-133 - Drug Profile
GXG-8 - Drug Profile
ibodutant - Drug Profile
IMSUTMR-1501 - Drug Profile
infectious diarrhea [serotype H11] vaccine - Drug Profile
LJN-452 - Drug Profile
obeticholic acid - Drug Profile
octreotide acetate - Drug Profile
octreotide acetate MAR - Drug Profile
Peptide to Activate NHE-3 for Diarrhea - Drug Profile
PF-06425090 - Drug Profile
prulifloxacin - Drug Profile
PZ-7475 - Drug Profile
RBX-2660 - Drug Profile
RDX-98940 - Drug Profile
RECCE-355 - Drug Profile
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile
Recombinant Proteins for Infectious Diarrhea - Drug Profile
ribaxamase - Drug Profile
ridinilazole - Drug Profile
rifamycin CR - Drug Profile
Rx-100 - Drug Profile
Small Molecule to Block CFTR for Diarrhoea - Drug Profile
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
Small Molecules for Microbial Infections - Drug Profile
Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile
Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile
SYN-006 - Drug Profile
SYN-007 - Drug Profile
Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile
Typhetec - Drug Profile
Vaccine 1 for Diarrhea - Drug Profile
Vaccine 2 for Diarrhea - Drug Profile
Vaccine for Traveler's Diarrhea - Drug Profile
Vaccine for Traveler's Diarrhea - Drug Profile
Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile
Yersinia pestis vaccine - Drug Profile
Diarrhea - Dormant Projects
Diarrhea - Discontinued Products
Diarrhea - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diarrhea, H2 2016
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016
Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
Diarrhea - Pipeline by Actelion Ltd, H2 2016
Diarrhea - Pipeline by Aegis Therapeutics, LLC, H2 2016
Diarrhea - Pipeline by AlbireoPharma, H2 2016
Diarrhea - Pipeline by Allergan Plc, H2 2016
Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2016
Diarrhea - Pipeline by Ardelyx, Inc., H2 2016
Diarrhea - Pipeline by Assembly Biosciences, Inc., H2 2016
Diarrhea - Pipeline by Codagenix, Inc., H2 2016
Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016
Diarrhea - Pipeline by DesignMedix, Inc., H2 2016
Diarrhea - Pipeline by DiscoveryBiomed, Inc., H2 2016
Diarrhea - Pipeline by Genextra S.p.a., H2 2016
Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2016
Diarrhea - Pipeline by GP Pharm, S.A., H2 2016
Diarrhea - Pipeline by Mucosis B.V., H2 2016
Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
Diarrhea - Pipeline by Novartis AG, H2 2016
Diarrhea - Pipeline by Pfizer Inc., H2 2016
Diarrhea - Pipeline by Prokarium Limited, H2 2016
Diarrhea - Pipeline by Protagonist Therapeutics Inc., H2 2016
Diarrhea - Pipeline by Rebiotix Inc., H2 2016
Diarrhea - Pipeline by Recce Pty Ltd, H2 2016
Diarrhea - Pipeline by RxBio, Inc., H2 2016
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2016
Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2016
Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2016
Diarrhea - Pipeline by Synthetic Biologics, Inc., H2 2016
Diarrhea - Pipeline by Syntiron LLC, H2 2016
Diarrhea - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diarrhea - Dormant Projects, H2 2016
Diarrhea - Dormant Projects (Contd..1), H2 2016
Diarrhea - Dormant Projects (Contd..2), H2 2016
Diarrhea - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Diarrhea, H2 2016
Number of Products under Development for Diarrhea - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

A. Menarini Industrie Farmaceutiche Riunite Srl
Ache Laboratorios Farmaceuticos S/A
Actelion Ltd
Aegis Therapeutics, LLC
AlbireoPharma
Allergan Plc
Anatara Lifesciences Limited
Ardelyx, Inc.
Assembly Biosciences, Inc.
Codagenix, Inc.
Cosmo Pharmaceuticals S.p.A
DesignMedix, Inc.
DiscoveryBiomed, Inc.
Genextra S.p.a.
GlaxoSmithKline Plc
GP Pharm, S.A.
Mucosis B.V.
Nippon Shinyaku Co., Ltd.
Novartis AG
Pfizer Inc.
Prokarium Limited
Protagonist Therapeutics Inc.
Rebiotix Inc.
Recce Pty Ltd
RxBio, Inc.
Scandinavian Biopharma Holding AB
Sigmoid Pharma Limited
Summit Therapeutics Plc
Synthetic Biologics, Inc.
Syntiron LLC
Tasly Pharmaceutical Group Co., Ltd.
Skip to top


Diarrhea - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 186 pages
Infectitious Diarrhea - Pipeline Review, H1 2014 US$ 1,500.00 May, 2014 · 76 pages
Infectitious Diarrhea - Pipeline Review, H2 2014 US$ 1,600.00 Nov, 2014 · 82 pages
Mucosis B.V. - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 27 pages
DiscoveryBiomed, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 21 pages

Ask Your Question

Diarrhea - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: